Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models.

Chiorazzi A, Wozniak KM, Rais R, Wu Y, Gadiano AJ, Farah MH, Liu Y, Canta A, Alberti P, Rodriguez-Menendez V, Meregalli C, Fumagalli G, Monza L, Pozzi E, Vornov JJ, Polydefkis M, Pietra C, Slusher BS, Cavaletti G.

Eur J Pharmacol. 2018 Dec 5;840:89-103. doi: 10.1016/j.ejphar.2018.09.029. Epub 2018 Sep 27.

PMID:
30268665
2.

We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine.

Lemberg KM, Vornov JJ, Rais R, Slusher BS.

Mol Cancer Ther. 2018 Sep;17(9):1824-1832. doi: 10.1158/1535-7163.MCT-17-1148. Review.

PMID:
30181331
3.

Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery.

Wozniak KM, Vornov JJ, Wu Y, Liu Y, Carozzi VA, Rodriguez-Menendez V, Ballarini E, Alberti P, Pozzi E, Semperboni S, Cook BM, Littlefield BA, Nomoto K, Condon K, Eckley S, DesJardins C, Wilson L, Jordan MA, Feinstein SC, Cavaletti G, Polydefkis M, Slusher BS.

Cancer Res. 2018 Feb 1;78(3):817-829. doi: 10.1158/0008-5472.CAN-17-1467. Epub 2017 Nov 30.

4.

FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities.

Rais R, Jiang W, Zhai H, Wozniak KM, Stathis M, Hollinger KR, Thomas AG, Rojas C, Vornov JJ, Marohn M, Li X, Slusher BS.

JCI Insight. 2016 Aug 4;1(12). pii: e88634.

5.

Still NAAG'ing After All These Years: The Continuing Pursuit of GCPII Inhibitors.

Vornov JJ, Hollinger KR, Jackson PF, Wozniak KM, Farah MH, Majer P, Rais R, Slusher BS.

Adv Pharmacol. 2016;76:215-55. doi: 10.1016/bs.apha.2016.01.007. Epub 2016 Mar 18. Review.

PMID:
27288079
6.

Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity.

Wozniak KM, Vornov JJ, Wu Y, Nomoto K, Littlefield BA, DesJardins C, Yu Y, Lai G, Reyderman L, Wong N, Slusher BS.

Cancer Res. 2016 Jun 1;76(11):3332-9. doi: 10.1158/0008-5472.CAN-15-2525. Epub 2016 Apr 13.

7.

Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist.

Garner R, Gopalakrishnan S, McCauley JA, Bednar RA, Gaul SL, Mosser SD, Kiss L, Lynch JJ, Patel S, Fandozzi C, Lagrutta A, Briscoe R, Liverton NJ, Paterson BM, Vornov JJ, Mazhari R.

Pharmacol Res Perspect. 2015 Dec 23;3(6):e00198. doi: 10.1002/prp2.198. eCollection 2015 Dec. Review.

8.

Gastrointestinal delivery of propofol from fospropofol: its bioavailability and activity in rodents and human volunteers.

Wozniak KM, Vornov JJ, Mistry BM, Wu Y, Rais R, Slusher BS.

J Transl Med. 2015 May 29;13:170. doi: 10.1186/s12967-015-0526-9.

9.

Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism.

Vornov JJ, Wozniak KM, Wu Y, Rojas C, Rais R, Slusher BS.

J Pharmacol Exp Ther. 2013 Sep;346(3):406-13. doi: 10.1124/jpet.113.205039. Epub 2013 Jun 17.

10.

The orally active glutamate carboxypeptidase II inhibitor E2072 exhibits sustained nerve exposure and attenuates peripheral neuropathy.

Wozniak KM, Wu Y, Vornov JJ, Lapidus R, Rais R, Rojas C, Tsukamoto T, Slusher BS.

J Pharmacol Exp Ther. 2012 Dec;343(3):746-54. doi: 10.1124/jpet.112.197665. Epub 2012 Sep 17.

PMID:
22988061
11.

Sedation with GPI 15715, a water-soluble prodrug of propofol, using target-controlled infusion in volunteers.

Fechner J, Ihmsen H, Schiessl C, Jeleazcov C, Vornov JJ, Schwilden H, Schüttler J.

Anesth Analg. 2005 Mar;100(3):701-6, table of contents. Retraction in: Anesth Analg. 2010 Apr 1;110(4):1238.

PMID:
15728055
12.

Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion.

Fechner J, Ihmsen H, Hatterscheid D, Jeleazcov C, Schiessl C, Vornov JJ, Schwilden H, Schüttler J.

Anesthesiology. 2004 Sep;101(3):626-39. Erratum in: Anesthesiology. 2008 Nov;109(5):940. Retraction in: Struys MM, Fechner J, Schüttler J, Schwilden H. Anesthesiology. 2010 Apr;112(4):1056-7. Anesthesiology. 2010 Apr;112(4):1058.

PMID:
15329587
13.

Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers.

Fechner J, Ihmsen H, Hatterscheid D, Schiessl C, Vornov JJ, Burak E, Schwilden H, Schüttler J.

Anesthesiology. 2003 Aug;99(2):303-13. Erratum in: Anesthesiology. 2008 Nov;109(5):940. Retraction in: Struys MM, Fechner J, Schüttler J, Schwilden H. Anesthesiology. 2010 Apr;112(4):1056-7. Anesthesiology. 2010 Apr;112(4):1058.

PMID:
12883403
14.

Glutamate carboxypeptidase II inhibition as a novel therapeutic target.

Rojas C, Thomas AG, Majer P, Tsukamoto T, Lu XM, Vornov JJ, Wozniak KM, Slusher BS.

Adv Exp Med Biol. 2003;524:205-13. Review. No abstract available.

PMID:
12675241
15.

N-Acetylated alpha-linked acidic dipeptidase converts N-acetylaspartylglutamate from a neuroprotectant to a neurotoxin.

Thomas AG, Vornov JJ, Olkowski JL, Merion AT, Slusher BS.

J Pharmacol Exp Ther. 2000 Oct;295(1):16-22.

PMID:
10991955
16.

Blockade of NAALADase: a novel neuroprotective strategy based on limiting glutamate and elevating NAAG.

Vornov JJ, Wozniak K, Lu M, Jackson P, Tsukamoto T, Wang E, Slusher B.

Ann N Y Acad Sci. 1999;890:400-5.

PMID:
10668445
17.

Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury.

Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Harukuni I, Bhardwaj A, Traystman RJ, Robinson MB, Britton P, Lu XC, Tortella FC, Wozniak KM, Yudkoff M, Potter BM, Jackson PF.

Nat Med. 1999 Dec;5(12):1396-402.

PMID:
10581082
18.

Toxicity induced by a polyglutamated folate analog is attenuated by NAALADase inhibition.

Thomas AG, Olkowski JL, Vornov JJ, Slusher BS.

Brain Res. 1999 Oct 2;843(1-2):48-52.

PMID:
10528109
19.

Cerebellar top-of-the-basilar syndrome.

Silverman IE, Geschwind MD, Vornov JJ.

Clin Neurol Neurosurg. 1998 Dec;100(4):296-8.

PMID:
9879857
20.

Ion channels and exchangers that mediate ischemic neuronal injury.

Vornov JJ.

Curr Opin Neurol. 1998 Feb;11(1):39-43. Review.

PMID:
9484615
21.
23.
25.

Delayed protection by MK-801 and tetrodotoxin in a rat organotypic hippocampal culture model of ischemia.

Vornov JJ, Tasker RC, Coyle JT.

Stroke. 1994 Feb;25(2):457-64; discussion 464-5.

PMID:
8303757
28.

The non-excitatory mechanisms of glutamate induced neurotoxicity.

Coyle JT, Murphy TH, Puttfarcken PS, Lyons EW, Vornov JJ.

Epilepsy Res. 1991 Oct;10(1):41-8. Review. No abstract available.

PMID:
1686428
29.
30.

Glutamate neurotoxicity and the inhibition of protein synthesis in the hippocampal slice.

Vornov JJ, Coyle JT.

J Neurochem. 1991 Mar;56(3):996-1006.

PMID:
1671589
31.

Selective release of N-acetylaspartylglutamate from rat optic nerve terminals in vivo.

Tsai G, Stauch BL, Vornov JJ, Deshpande JK, Coyle JT.

Brain Res. 1990 Jun 4;518(1-2):313-6.

PMID:
1975216
33.

Supplemental Content

Loading ...
Support Center